Latest News and Press Releases

- Dr. Ludwig brings over 20 years of leadership and management expertise from Eli Lilly and Company and Imclone Systems, Inc. in oncology antibody therapeutics discovery and development where he...

Actinium scheduled to present on Monday, January 8, 2018 at 10:00 AM PT NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) --  Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the...

Actinium expects enhanced awareness of Iomab-B at ASH annual meeting and expanded site activity to enable completion of trial enrollment by end of 2018, in-line with prior forecast NEW YORK, Dec. ...

Higher cell death observed with Actinium-225 labeled daratumumab with up to ten-fold higher potency as compared to naked daratumuambARC of Daratumumab-Actinium-225 labeled with high yield, high...

Analysis of patient data from a large U.S. library revealed that twenty-five percent of Multiple Myeloma patients have CD33 expression on their multiple myeloma cells supporting the rational for...

69% Overall Response Rate and 98% median reduction in bone marrow blasts reported with Actimab-A given at 2.0 µCi/kg/fraction as a single agent Minimal extramedullary toxicities observed; No evidence...

Phase 2 clinical trial planned for 2018, Actimab-MDS intended to be a bridge to a bone marrow transplant, the only curative treatment option for patients with myelodysplastic syndromeTrial principal...

- Poster presentation to detail results from ongoing Phase 2 trial for Actimab-A, Actinium’s CD33 targeting ARC or Antibody Radio-Conjugate, designed to explore Actimab-A’s efficacy in patients newly...

- AWE Program launched post successful demonstration of Actinium’s “Biobetter” capabilities as evidenced by superior experimental results with actinium-225 labeled daratumumab when compared to...

- Dr. Gail Roboz, Director of the Leukemia Program and Professor of Medicine at Weill Cornell Medical College and NewYork-Presbyterian will introduce the planned clinical initiative on the webcast  -...